Abstract Background A previous European Headache Federation (EHF) guideline
addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide …

Medication overuse in primary headache disorders is a worldwide phenomenon and has a
role in the chronification of headache disorders. The burden of disease on individuals and …

Background and aim Monoclonal antibodies acting on the calcitonin gene-related peptide or
on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been …

Background This narrative review aims to discuss several common neurological and
psychiatric disorders that show comorbidity with migraine. Not only can we gain …

Background and purpose New prophylactics for migraine, targeting calcitonin gene‐related
peptide (CGRP), have recently emerged. Real‐world data are important for a …

Botulinum toxin A (BTA) is widely used as treatment of chronic migraine. Efficacy in studies,
however, was only modest and likely influenced by unblinding due to BTA-induced removal …

Background Central sensitisation is an important mechanism in migraine chronification. It is
presumed to occur in second and third order neurons sequentially, resulting in an …

It is a widely accepted idea that medications taken to relieve acute headache pain can
paradoxically worsen headache if used too often. This type of secondary headache is …

Background: Calcitonin gene-related peptide (CGRP) targeted therapies are an important
breakthrough in migraine prevention. Randomized clinical trials, post-hoc analyses, and …

Background Transcranial direct current stimulation was suggested to provide beneficial
effects in chronic migraine, a condition often associated with medication overuse for which …